# Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer

> **NCT00401752** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 397 (actual)

## Conditions studied

- Gastric Ulcer

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Ranitidine

## Key facts

- **NCT ID:** NCT00401752
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** 2008-11
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2010-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401752, "Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00401752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*